Vertex Pharmaceuticals | VRTX - Interest Income


Vertex Pharmaceuticals reported $114.8M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
AbbVie USD 72M 13M Mar/2026
Acadia Pharmaceuticals USD 8.06M 277K Mar/2026
Agios Pharmaceuticals USD 10.8M 1.62M Mar/2026
Alnylam Pharmaceuticals USD 26.6M 32K Mar/2026
Arrowhead Research USD 16.87M 7.18M Mar/2026
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Gilead Sciences USD 95M 0 Mar/2026
Incyte USD 38.12M 4.43M Jun/2026
Insmed USD 765K 55K Sep/2024
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
J&J USD 2.27 0.13 Jun/2026
Merck USD 35M 34M Mar/2026
Moderna USD 72M 2M Mar/2026
Pfizer USD -0.04 115M Jun/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 183.3M 200K Jun/2026
Sanofi EUR 77M 17M Jun/2026
Sarepta Therapeutics USD 7M 1.74M Mar/2026
Ultragenyx Pharmaceutical USD 6M 512K Mar/2026
United Therapeutics USD 31.5M 10.3M Jun/2026
Vertex Pharmaceuticals USD 114.8M 7.1M Mar/2026